

High Sensitivity Analysis of Opioids in Oral Fluid Using ionKey/MS

Gregory T. Roman, Robert Lee, James P. Murphy, and Michelle Wood

GOAL

To separate and quantify opioids at very low levels in oral fluid with superior sensitivity compared to 2.1 mm I.D. chromatography.

BACKGROUND

Over the past three decades oral fluid has emerged as a highly valuable biological specimen and is commonly used in numerous settings, including therapeutic drug monitoring, and workplace and roadside drug testing. Oral fluid analysis has many advantages compared with other matrices such as blood or urine. These include collection convenience and reduced sample collection overheads.

Whilst oral fluid itself is a relatively clean matrix, comprising mostly of water and a small percentage of proteins, the popularity of the specimen has led to the development of a large variety of collection devices, aiming to further simplify and standardize collection. Typically these devices will include additives and preservatives to improve the stability of the collected sample. One of the key analytical challenges with oral fluid analysis is the limited amount of sample available for testing compared with blood or urine, requiring very sensitive instrumentation to reach the low levels of detection and quantification. The ionKey/MS™ System offers the capability of improving sensitivity in sample-limited situations, making it ideally suited for this application.

The ionKey/MS System facilitates high sensitivity and robust analysis of opioids in oral fluid.



Figure 1. The ionKey/MS System with the ACQUITY UPLC® M-Class System and the Xevo® TQ-S Mass Spectrometer.

Time (min)	Flow rate (µL/min)	Composition A (%)	Composition B (%)	Curve
0	3	95	5	Initial
6	3	55	45	6
8	3	15	85	6
11	3	95	5	6
Mobile phase A: Water, 0.1% formic acid				
Mobile phase B: Acetonitrile, 0.1% formic acid				
Trapping conditions				
1 min	15	99.50%	0.50%	6

Table 1. LC-MS conditions.

Performing analysis of oral fluid samples taken directly from a collection device provides a streamlined method for reducing workflow and increasing throughput. The use of a trapping column prior to analytical separation allows the removal of additives (e.g., surfactants) that can cause suppression in LC-MS and lead to reduced sensitivity. Trapping can also provide improved peak shape for hydrophilic small molecules, and crucially enables enhanced loading for ionKey/MS. Furthermore, the trapping column adds a layer of protection similar to that of a guard column, for precious downstream consumables, making the analytical method more robust.

THE SOLUTION

Here we demonstrate the separation and high sensitivity detection of opioids in oral fluid with the ionKey/MS System comprised of an ACQUITY UPLC M-Class System in combination with a Xevo TQ-S Mass Spectrometer. Preliminary trapping was achieved using an ACQUITY UPLC M-Class HSS T3, 100Å, 1.8 µm, 300 µm x 50 mm Trap Column (P/N 186008029) in combination with a 5 µL loop (Figure 1 and Table 1). Analytical separation was




Figure 2. MRM chromatograms for 25 opioids and metabolites.




Figure 3. Calibration curve and LOQ of morphine spiked into oral fluid.

performed using an iKey™ HSS T3, 100Å, 1.8 µm, 150 µm x 100 mm (P/N 186007261) Separation Device. Trapping-enabled quantitative analysis of 25 early eluting opioids and metabolites in oral fluid is illustrated in Figure 2.

Figure 3 shows the calibration curve and LOQ of morphine spiked into oral fluid. The LOQ (based on a signal to noise ratio of 10:1) was calculated to be 13 pg/mL. The peak width of morphine, at 10% peak height, was 3.0 seconds and is shown in the insert in Figure 2. Figure 4 compares morphine detected using an ionKey/MS System to an ACQUITY UPLC 2.1 mm I.D. Column. The ionKey/MS System shows an improvement of 9X over the analogous 2.1 mm column format. The trapping column and separation device used in these studies were specifically chosen for their increased retentivity for hydrophilic opioids and metabolites. These comparisons were performed with equivalent injection volumes of 5 µL.

SUMMARY

The utilization of the ionKey/MS System enabled a 9X improvement in sensitivity for morphine compared to an ACQUITY UPLC 2.1 mm I.D. Column when injecting the same volume. In addition to morphine, many of the glucuronides were also identified as having improved sensitivity.




Figure 4. Comparison of morphine detection using an ionKey/MS System to an ACQUITY UPLC 2.1 mm I.D. Column.

Specifically, morphine-3b glucuronide was demonstrated to be baseline separated from morphine, with a sensitivity improvement of 11X. Whilst this particular glucuronide may not be relevant for oral fluid, the increased sensitivity presents a clear advantage for analysis in other biological specimens.

The assay described here is robust and reproducible using oral fluid matrix injections of over 500 injections. Retention time reproducibilities were <1% RSD, while peak area reproducibility of morphine was 11.1% RSD.

Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, Xevo, and ACQUITY UPLC are registered trademarks of Waters Corporation. IonKey/MS and iKey are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2016 Waters Corporation. Produced in the U.S.A. January 2016 720005296EN TC-PDF

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com